Ad
related to: warfarin to apixaban- 109 S High St #100, Columbus, OH · Directions · (614) 224-4261
Search results
Results from the WOW.Com Content Network
Compared to warfarin it has fewer interactions with other medications. [10] It is a direct factor Xa inhibitor. [6] In 2007, Pfizer and Bristol-Myers Squibb began the development of apixaban as an anticoagulant. [11] Apixaban was approved for medical use in the European Union in May 2011, and in the United States in December 2012.
The p-methoxy group of apixaban connects to S1 pocket of FXa but does not appear to have any interaction with any residues in this region of FXa. The pyrazole N-2 nitrogen atom of apixaban interacts with Gln-192 and the carbonyl oxygen interacts with Gly-216. The phenyl lactam group of apixaban is positioned between Tyr-99 and Phe-174 and due ...
Warfarin, sold under the brand name Coumadin among others, is an anticoagulant medication. [12] ... such as dabigatran, apixaban, edoxaban, and rivaroxaban, ...
ELIQUIS ® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at ...
Subanalysis of Phase III ARISTOTLE Trial of Eliquis® (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart ...
U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...
The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [3] [14] A naturally occurring inhibitor of factor Xa was reported in 1971 by Spellman et al. from the dog hookworm. [15]
Dabigatran is an oral direct thrombin inhibitor. Dabigatran (Pradaxa) was found to be noninferior to Warfarin in prevention of ischemic stroke, as well as intracranial hemorrhage risk and overall mortality for non-valvular atrial fibrillation according to the RE-LY trial. [9]
Ad
related to: warfarin to apixaban- 109 S High St #100, Columbus, OH · Directions · (614) 224-4261
